review
focus
recent
progress
understand
filoviru
protein
structurefunct
impact
antivir
research
focu
surfac
glycoprotein
gp
differ
role
filoviru
entri
first
describ
latest
advanc
character
gp
geneoverlap
protein
sgp
ssgp
dpeptid
compar
filoviru
surfac
gp
protein
term
structur
synthesi
function
bear
potenti
drugdesign
discoveri
small
organ
compound
inhibit
filoviru
entri
current
activ
field
although
earli
stage
develop
antivir
drug
ebola
marburg
viru
entri
might
prove
essenti
reduc
outbreakassoci
fatal
rate
postexposur
treatment
suspect
confirm
case
entri
host
cell
via
complex
mechan
date
partial
understood
draw
present
knowledg
numer
research
group
recent
develop
antivir
strategi
aim
inhibit
viral
entri
review
present
current
knowledg
filoviru
glycoprotein
compar
structur
associ
function
briefli
place
filovirus
viral
classif
nomenclatur
describ
solubl
gp
deriv
sgp
ssgp
dpeptid
review
structur
featur
surfac
gp
detail
step
step
mechan
gp
trigger
viru
entri
part
aim
highlight
relationship
structur
featur
role
variou
phase
filoviru
entri
process
attent
idiosyncrasi
within
famili
filovirida
lastli
recapitul
exist
ongo
antivir
strategi
order
connect
mechan
action
structurefunct
analysi
aim
potent
antifiloviru
therapi
famili
filovirida
belong
neg
strand
nonseg
nn
rna
virus
mononegaviral
order
famili
group
highli
pathogen
virus
found
marburgviru
ebolaviru
genera
ascenzi
et
al
respons
sever
hemorrhag
fever
well
genu
cuevaviru
negredo
et
al
latter
found
far
form
rna
sequenc
bat
fig
marburgviru
genu
repres
virus
within
singl
speci
marburg
marburgviru
marburg
viru
marv
first
filoviru
genu
speci
discov
relat
outbreak
frankfurt
germani
belgrad
yugoslavia
upon
import
infect
monkey
uganda
marburg
germani
siegert
et
al
ebolaviru
genu
consist
five
viru
speci
known
zair
ebolaviru
ebola
viru
ebov
first
ebolaviru
speci
identifi
democrat
republ
congo
formerli
northern
zair
near
ebola
river
sudan
ebolaviru
sudan
viru
sudv
forest
ebolaviru
forest
viru
tafv
bundibugyo
ebolaviru
bundibugyo
viru
bdbv
reston
ebolaviru
reston
viru
restv
accord
new
nomenclatur
kuhn
et
al
restv
describ
caus
human
diseas
yet
speci
includ
marv
highli
pathogen
fatal
rate
rang
feldmann
geisbert
cuevaviru
genu
establish
discoveri
sequenc
like
belong
new
filoviru
lloviu
cuevaviru
lloviu
viru
llov
presum
infect
bat
asturia
spain
negredo
et
al
sinc
novel
entri
filoviru
phylogeni
littl
known
biolog
put
infect
human
high
infect
abil
impair
immun
system
feldmann
geisbert
ramanan
et
al
filovirus
trigger
abrupt
onset
symptom
includ
fever
headach
myalgia
gastrointestin
disord
next
hemorrhag
manifest
aris
peak
ill
shock
convuls
coagulopathi
multiorgan
failur
appear
later
fatal
mani
case
feldmann
geisbert
nina
unfortun
approv
antivir
vaccin
avail
yet
although
signific
progress
made
late
respect
mendoza
et
al
support
treatment
rehydr
control
fever
pain
might
help
patient
overcom
infect
late
lot
effort
put
togeth
identifi
key
viral
target
order
inhibit
viral
cycl
help
cure
infect
choi
croyl
filovirus
share
common
genom
organ
nn
rna
genom
around
kb
carri
seven
main
gene
lead
synthesi
differ
viral
protein
fig
ascenzi
et
al
protein
essenti
establish
infect
lead
effici
viru
replic
fig
sole
surfac
protein
gp
trigger
first
step
cell
infect
requir
attach
factor
present
surfac
target
dendrit
cell
dc
monocytesmacrophag
endotheli
cell
liver
sinusoid
lymph
node
sinus
attach
virion
intern
endosom
event
induc
fusion
feldmann
et
al
allow
releas
viral
particl
content
cytoplasm
nucleocapsid
compos
genom
rna
complex
nucleoprotein
np
two
cofactor
larg
protein
l
form
larg
macromolecular
complex
protect
rna
genom
facilit
genom
replicationtranscript
review
l
protein
harbor
rnadepend
rna
polymeras
rdrp
activ
essenti
genom
replic
transcript
addit
protein
carri
yet
uncharacter
enzymat
activ
involv
rna
transcript
modif
rna
cap
polyadenyl
protect
viral
mrna
degrad
detect
host
cell
innat
immun
guardian
liang
et
al
nucleoprotein
np
enwrap
protect
nn
rna
host
nucleas
protein
act
transcript
cofactor
polymeras
cofactor
replic
viral
genom
rna
transcript
nascent
viral
particl
assembl
process
mediat
matrix
protein
viru
bud
occur
cell
surfac
membran
process
involv
hijack
host
escrt
machineri
hartlieb
weissenhorn
noda
et
al
earli
stage
cell
infect
shown
mediat
class
viral
glycoprotein
gp
expos
viru
membran
surfac
review
lee
saphir
protein
synthes
precursor
gp
translat
edit
gp
open
read
frame
fig
cleav
yield
ectodomain
gp
fig
filoviru
genom
organ
filovirus
famili
nonseg
neg
singl
strand
rna
virus
includ
genera
ebolaviru
marburgviru
cuevaviru
respect
prototyp
virus
ebola
viru
ebov
marburg
viru
marv
lloviu
viru
llov
share
common
genom
organ
genom
kb
code
least
well
defin
monocistron
mrna
except
one
bicistron
mrna
llov
genom
ebov
marv
first
last
nucleotid
mrna
indic
wherea
llov
exact
mrna
end
still
unclear
length
roughli
estim
transmembran
fusion
domain
gp
viral
cell
entri
critic
point
infect
step
target
design
antivir
molecul
also
noteworthi
gp
gene
code
addit
protein
whose
function
complet
understood
mechan
drive
express
protein
describ
fig
gp
gene
fourth
gene
along
genom
everi
filoviru
sanchez
et
al
negredo
et
al
filoviru
gp
gene
encod
transmembran
protein
gp
local
viru
surfac
ebolavirus
presum
cuevavirus
unedit
edit
transcript
produc
sever
form
gp
togeth
host
furindepend
proteolysi
lead
express
addit
protein
solubl
gp
sgp
describ
ebolavirus
cuevavirus
small
solubl
gp
ssgp
fig
propos
edit
mechan
limit
surfac
gpassoci
cytotox
see
volchkov
et
al
mohan
et
al
rna
edit
ebolavirus
involv
slippag
region
compos
seven
consecut
templat
uridin
viral
polymeras
stutter
result
frameshift
middl
gp
sequenc
volchkov
et
al
sanchez
et
al
mehedi
et
al
inde
edit
mechan
recent
shown
regul
neighbor
sequenc
uridin
templat
probabl
synergi
transact
factor
mehedi
et
al
thu
ebolaviru
gp
gene
abl
gener
three
differ
mrna
code
protein
precursor
presgp
pregp
ssgp
ratio
approxim
respect
albeit
exact
ratio
cell
type
depend
fig
mehedi
et
al
ebolavirus
abund
product
unedit
transcript
presgp
mrna
lead
synthesi
protein
precursor
presgp
remark
incorpor
virion
structur
per
se
precursor
kda
cleav
cellular
proteas
furin
famili
cterminu
rxrri
conserv
motif
posit
cleavag
form
final
sgp
dpeptid
fig
aminoacid
carboxytermin
dfragment
subsequ
highli
modifi
posttransl
level
oglycosyl
secret
although
dpeptid
function
complet
understood
yet
suggest
peptid
regul
filoviru
entri
sinc
express
limit
infect
filoviruspermiss
cell
moreov
base
silico
analysi
peptid
also
propos
act
virul
factor
form
lytic
viroporin
although
experiment
evid
function
lack
gallah
garri
effort
devot
character
sgp
share
first
ntermin
residu
gp
ssgp
volchkov
et
al
cleavag
sgp
monom
bind
parallel
orient
mean
two
disulfid
bond
involv
residu
falzarano
et
al
due
lack
transmembran
domain
sgp
form
solubl
dimer
mainli
nglycosyl
kda
role
recent
investig
vitro
vivo
inde
sgp
suggest
virul
factor
although
current
entir
clear
whether
case
one
studi
indic
abolish
sgp
product
lead
notic
attenu
viru
howev
fast
emerg
revert
vivo
vitro
certain
cell
line
sgp
product
reduc
introduc
genotyp
ie
uridin
residu
viru
genom
lead
product
predominantli
mrna
edit
site
suggest
import
role
sgp
biolog
ebolavirus
volchkova
et
al
kugelman
et
al
hoenen
et
al
tsuda
et
al
vitro
sgp
exert
vascular
effect
notabl
restor
barrier
function
suggest
antiinflammatori
role
wahljensen
et
al
howev
relev
find
current
clear
also
increas
evid
sgp
might
reduc
viral
cytotox
limit
amount
express
gp
see
iwasa
et
al
mohan
et
al
final
shown
secret
sgp
might
also
lead
immun
subvers
act
decoy
antibodi
direct
gp
ito
et
al
mohan
et
al
howev
role
sgp
review
de
la
vega
et
al
investig
requir
ascertain
relev
realli
ebolaviru
biolog
whether
protein
repres
potenti
antivir
target
anoth
protein
product
ebolaviru
cuevaviru
gp
gene
ssgp
small
protein
kda
synthes
transcript
either
one
adenosin
delet
two
ad
transcript
edit
fig
shown
ssgp
secret
kda
dimer
carri
disulfid
linkag
monom
latter
larg
nglycosyl
mehedi
et
al
although
ssgp
share
similar
structur
properti
sgp
gp
seem
exert
antiinflammatori
function
endotheli
cell
mehedi
et
al
role
viral
pathogen
well
potenti
antivir
target
remain
unclear
schemat
ultrastructur
filovir
particl
viral
protein
assembl
lead
format
filament
viral
particl
abl
infect
host
target
cell
carri
requir
materi
complet
viral
replic
cycl
surfac
glycoprotein
gp
trigger
viral
attach
entri
nucleocapsid
compon
rnaprotect
nucleoprotein
np
viral
protein
vp
larg
l
polymeras
releas
cytoplasm
replic
transcript
result
synthesi
new
viral
genom
protein
aid
nucleocapsid
assembl
matrix
protein
orchestr
format
new
virion
gp
rna
transcript
code
gp
precursor
transcript
result
polymeras
slippag
templat
result
addit
adenosin
ebolaviru
presum
cuevaviru
gp
mrna
unlik
case
unedit
marburgviru
mrna
fig
volchkov
et
al
sanchez
et
al
mrna
translat
gp
precursor
transit
endoplasm
reticulum
golgi
apparatu
cleav
furinlik
proteas
two
protein
gp
gp
posit
conserv
cleavag
site
variabl
insid
famili
filovirida
gene
structur
function
organ
homolog
volchkov
et
al
manicassami
et
al
maruyama
et
al
inde
two
protein
togeth
form
trimer
chalic
structur
made
three
gp
three
gp
subunit
fig
assembl
gp
gp
gp
gp
interact
simmon
bowl
chalic
shape
gp
subunit
gp
organ
anchor
complex
membran
trimer
gp
bound
disulfid
bond
gp
gp
describ
ebolavirus
lee
et
al
lead
complex
metast
intricaci
ectodomain
gp
constitut
core
protein
mucinlik
domain
mld
larg
glycosyl
simmon
mld
structur
defin
yet
slight
differ
term
sequenc
length
posit
rel
cleavag
site
volchkov
et
al
sanchez
et
al
differ
filoviru
genera
inde
ebolavirus
hold
mld
singl
unit
gp
wherea
marburgvirus
cuevavirus
carri
two
block
one
gp
gp
despit
differ
propos
featur
play
common
role
attach
viru
via
lectin
immun
escap
hide
potenti
conserv
epitop
simmon
actual
known
epitop
target
neutral
antiebolaviru
antibodi
shown
lie
uncov
domain
present
interfac
gp
gp
lee
et
al
dia
et
al
similarli
antibodi
identifi
marburgviru
diseas
survivor
target
key
residu
receptor
bind
mask
case
ebolavirus
mld
access
case
marburgvirus
hashiguchi
et
al
fact
crossreact
antibodi
target
receptorbind
site
rb
found
marburgviru
diseas
survivor
ebolaviru
diseas
survivor
use
argument
strengthen
case
function
mld
immun
escap
core
gp
subdivid
three
domain
glycan
cap
head
base
lee
et
al
glycan
cap
outer
part
gp
form
chalic
head
supposedli
help
structur
metast
prefus
conform
part
expos
host
membran
surfac
carri
put
rb
base
subdomain
support
linkag
gp
stabil
metast
prefus
conform
thu
gp
requir
structur
featur
mediat
viral
attach
cell
receptor
see
transmembran
gp
protein
anchor
complex
viral
membran
also
manag
viru
entri
fusion
fig
simmon
structurefunct
complex
well
describ
ebolavirus
lee
et
al
briefli
structur
incorpor
transmembran
domain
short
cytoplasm
tail
intern
fusion
loop
defin
disulfid
bound
gp
two
heptad
repeat
region
surround
fusion
peptid
domain
constitut
unstabl
prefus
conform
gp
rearrang
low
ph
trigger
fusion
maintain
structur
prefus
state
gp
head
pack
gp
hydrophob
fusion
peptid
stabil
gp
featur
viral
particl
process
endosom
proteas
lead
receptor
recognit
trigger
fusion
releas
nucleocapsid
host
cytoplasm
neg
strand
rna
transcrib
messeng
rna
allow
translat
protein
synthesi
occur
facilit
secondari
transcript
well
replic
complimentari
posit
sens
rna
gp
transit
rough
endoplasm
reticulumgolgi
apparatu
pathway
bud
occur
divert
host
traffick
machineri
lead
format
new
virion
clearli
describ
yet
marburgvirus
cuevavirus
sequenc
align
vitro
data
suggest
similar
conform
entryfus
mechan
manicassami
et
al
maruyama
et
al
liu
et
al
gp
fusion
protein
mediat
filoviru
cell
entri
gp
orchestr
viral
entri
seen
three
step
mechan
attach
uptak
fusion
fig
olejnik
et
al
attach
filoviru
target
cell
mediat
gp
ident
main
cellular
attach
factor
remain
unclear
review
takada
fact
appear
numer
protein
cell
surfac
fulfil
function
first
ctype
lectin
famili
member
hmgl
immatur
dendrit
cell
macrophag
takada
et
al
matsuno
et
al
asialoglycoprotein
dcsign
lsign
lsectin
ebolaviru
gp
gene
product
gp
gene
roughli
similar
ebolavirus
marburgvirus
cuevovirus
notabl
except
marburgviru
gp
gene
undergo
transcript
edit
encod
gp
ebolaviru
gp
gene
like
cuevoviru
gp
gene
contain
polyu
repeat
stutter
region
sr
facilit
edit
mechan
result
synthesi
three
differ
mrna
lead
synthesi
sgp
shown
left
gp
shown
center
ssgp
shown
right
mrna
contain
signal
sequenc
ss
code
sequenc
differ
protein
share
common
sequenc
grey
lead
ident
aminoterminu
gpprotein
mrna
translat
preprotein
transit
endoplasm
reticulum
golgi
apparatu
intracellular
traffick
signal
peptid
sp
remov
protein
glycosyl
nand
oglycosyl
gp
matur
cleavag
furinlik
proteas
gp
red
gp
green
mucinlik
domain
part
gp
red
ebolavirus
wherea
marburgvirus
cuevovirus
part
gp
gp
togeth
gp
gp
form
gp
assembl
trimer
surfac
gp
shed
solubl
trimer
upon
cleavag
host
tnfaconvert
enzym
tace
three
protein
sgp
blue
dpeptid
purpl
ssgp
yellow
synthet
ebolavirus
presum
also
cuevovirus
dcsign
r
liver
endotheli
cell
lymphocyt
alvarez
et
al
lin
et
al
simmon
et
al
marzi
et
al
gramberg
et
al
gramberg
et
al
dominguezsoto
et
al
powlesland
et
al
maruyama
et
al
expect
interact
set
nand
olink
glycan
mld
glycan
cap
gp
sinc
lectin
increas
filoviru
attach
howev
bind
molecul
seem
suffici
trigger
viru
intern
marzi
et
al
matsuno
et
al
addit
b
integrin
propos
serv
attach
factor
ebolavirus
sinc
infect
decreas
presenc
antibodi
target
protein
cell
line
primari
cell
type
takada
et
al
simmon
et
al
howev
direct
interact
molecul
demonstr
yet
recent
studi
suggest
b
integrin
requir
gpmediat
bind
intern
rather
posit
regul
cathepsin
play
import
role
process
gp
fusioncompet
form
within
endosom
infect
cell
schornberg
et
al
axl
member
tam
receptor
famili
also
propos
coreceptor
ebov
attach
similarli
b
integrin
may
promot
viral
entri
indirectli
shimojima
et
al
schornberg
et
al
brindley
et
al
hunt
et
al
cellsurfac
molecul
tcell
immunoglobulin
mucin
describ
interact
ebolaviru
gp
lead
viru
intern
mollertank
et
al
yuan
et
al
rhein
et
al
nevertheless
despit
clearli
demonstr
role
epitheli
cell
antigenpres
cell
subset
significantli
express
respect
suggest
attach
factor
involv
filovirussuscept
cell
type
tam
could
target
phosphatidylserin
ptdser
expos
outer
leaflet
filoviru
membran
strengthen
interplay
promot
effici
attach
review
mollertank
mauri
final
last
attach
mechan
describ
reminisc
antibodydepend
enhanc
ade
process
filovirus
divert
virusspecif
antibodi
get
attach
immun
system
cell
cellular
fc
receptor
via
complement
compon
ligand
identifi
mammalian
cell
takada
et
al
takada
et
al
nakayama
et
al
interestingli
viral
pathogen
seem
correl
filoviru
ade
nakayama
et
al
case
appear
attach
requir
set
protein
interact
complex
manner
promot
entri
uptak
key
step
filoviru
entri
serv
transform
prefus
gp
conform
prime
gp
trigger
fusion
event
fig
first
intern
propos
involv
differ
endocyt
pathway
precis
mechan
controversi
past
sinc
clathrindepend
caveolindepend
uptak
shown
occur
bavari
et
al
empig
goldsmith
sanchez
bhattacharyya
et
al
bhattacharyya
et
al
howev
latest
data
support
filoviru
uptak
mechan
mainli
mediat
macropinocytosi
depend
among
factor
host
cell
viru
particl
size
nanbo
et
al
saeed
et
al
aleksandrowicz
et
al
intern
macropinocytosi
vesicl
rout
endosom
vesicl
host
cell
proteolyt
event
occur
prime
gp
fig
endosom
ebov
gp
sequenti
process
cystein
proteas
cathepsin
b
catb
andor
cathepsin
l
catl
acid
ph
reduc
condit
chandran
et
al
schornberg
et
al
brecher
et
al
concis
appear
ebov
bdbv
tafv
catb
remov
major
part
gp
glycan
cap
mld
proteolyt
event
slightli
differ
sudv
restv
marv
llov
catb
shown
dispens
chan
et
al
gnirss
et
al
xia
et
al
maruyama
et
al
ng
et
al
thought
catl
partial
remov
part
gp
cap
subsequ
proteolysi
e
catb
catl
andor
proteas
e
result
smaller
gp
form
less
kda
latest
structur
input
inform
regard
cathepsin
cleavag
becom
avail
inde
amongst
minor
differ
ebov
marv
gp
catb
cleavag
site
identifi
ebov
shown
disord
thu
potenti
easili
access
fig
ebolaviru
surfac
gp
conserv
among
famili
filovirida
surfac
gp
pdb
trimer
compos
three
dimer
gp
red
gp
green
form
chalic
viral
envelop
left
panel
present
surfac
represent
threedimension
structur
ebolaviru
gp
gp
gp
shown
red
green
respect
right
panel
highlight
conserv
residu
dark
red
light
red
dark
green
light
green
accord
conserv
deriv
sequenc
align
everi
filoviru
speci
use
hierarch
cluster
multialin
server
figur
show
conserv
residu
local
center
trimer
complex
indic
grey
dot
circl
contain
featur
prime
fusion
well
extern
domain
target
crossgenu
neutral
antibodi
marv
homolog
region
ahelix
hashiguchi
et
al
howev
remain
open
question
regard
filoviru
gp
proteolysi
process
sinc
proteas
also
propos
particip
process
much
cathepsin
work
done
use
gppseudotyp
vsv
retroviru
particl
work
infecti
ebolavirus
challeng
import
cathepsin
viral
life
cycl
particularli
viru
replic
vitro
well
vivo
shown
independ
catb
catl
cathepsin
knockout
mice
succumb
ebolaviru
challeng
albeit
vsv
infect
marzi
et
al
case
cleavag
trigger
increas
bind
infect
ebola
viru
unmask
potenti
rb
firstli
describ
residu
peptid
gp
lee
et
al
recent
niemannpick
protein
anchor
late
endosom
lysosom
protein
physiolog
implic
cholesterol
absorpt
homeostasi
shown
interact
region
gp
fig
white
schornberg
inde
latest
structur
data
defin
rb
neg
charg
crest
hydrophob
trough
apex
gp
trimer
interact
mostli
domain
c
loop
partial
domain
ntd
bornholdt
et
al
gong
et
al
zhao
et
al
structur
character
gp
interact
provid
key
inform
design
promis
antivir
strategi
importantli
analys
describ
crucial
receptor
potenti
determin
speci
suscept
filovirus
ng
et
al
hoffmann
et
al
ndungo
et
al
pave
way
toward
filovirusspecif
antivir
molecul
see
even
deeper
investig
need
mechan
filoviru
entri
interact
cleav
gp
endosom
environ
trigger
conform
chang
gp
initi
membran
fusion
fig
lee
et
al
kuroda
et
al
fusion
necessit
larg
conform
chang
repres
highenergi
barrier
gp
cleavag
lowph
environ
hypothes
gp
constraint
remov
metast
gp
histidin
proton
gener
energi
trigger
fusion
event
kampmann
et
al
lee
et
al
fig
surfac
gp
endosom
process
attach
mediat
interact
filoviru
surfac
protein
gp
pdb
variou
attach
factor
complex
intern
rout
endosom
gp
process
trigger
fusion
viral
host
membran
first
endosom
low
ph
environ
cathepsin
proteas
l
b
catl
catb
other
remov
mucinlik
region
mld
glycan
cap
gc
domain
gp
red
receptor
bind
domain
rdb
also
carri
gp
unmask
lead
interact
mainli
hydrophob
pocket
ntermin
domain
blue
endosom
protein
niemannpick
pdb
interact
togeth
partial
understood
molecular
event
remov
gp
constraint
gp
green
form
primedgp
capabl
induc
fusion
gp
heptad
repeat
region
rearrang
push
fusion
peptid
pink
anchor
host
membran
intermedi
prehairpin
conform
destabil
membran
bilay
foldingback
sixbundl
helic
conform
pdb
merg
membran
open
fusion
pore
releas
viral
nucleocapsid
markosyan
et
al
point
disord
hrr
rearrang
ahelic
helic
push
host
membran
anchor
hydrophob
fusion
peptid
target
membran
within
membran
key
residu
amongst
trigger
bilay
destabil
extend
prehairpin
intermedi
conform
fig
therefor
elong
gp
span
thu
branch
host
viral
membran
fusion
final
occur
collaps
intermedi
foldingback
conform
distort
viral
host
membran
simultan
rapproch
gp
act
clamp
reach
low
energi
state
character
six
helic
bundl
gp
hairpin
postfus
structur
fig
novel
conform
lead
merg
hemifus
stalk
open
fusion
pore
allow
releas
nucleocapsid
host
cytoplasm
fig
principl
function
gp
cell
infect
sever
line
evid
suggest
might
also
involv
pathogenesi
cellular
gp
relat
cytotox
event
occur
infect
cell
cytotox
reflect
round
cell
vitro
due
mask
variou
host
cell
surfac
molecul
takada
et
al
francica
et
al
mask
shown
glycan
umbrella
mediat
steric
shield
adhes
protein
mediat
surfaceexpress
gp
lead
loss
access
function
host
surfac
protein
reynard
et
al
francica
et
al
mask
adhes
molecul
lead
cell
detach
may
contribut
disrupt
blood
vessel
integr
hemorrhag
develop
filoviru
infect
inde
primari
endotheli
cell
cultur
overexpress
gp
transduct
adenoviru
vector
result
loss
adher
result
apoptosi
ray
et
al
addit
steric
shield
gp
also
affect
mhci
surfac
express
francica
et
al
phenomenon
also
known
occur
infect
primari
endotheli
cell
harcourt
et
al
might
alter
immun
cell
recruit
thu
may
particip
immun
suppress
inflammatori
dysfunct
link
filoviru
infect
harcourt
et
al
reynard
et
al
mention
sgp
shown
regul
gp
express
thank
transcript
edit
gp
gene
volchkov
et
al
mohan
et
al
interestingli
ebov
serial
passag
certain
cell
line
like
vero
cell
gp
gene
get
modifi
predominantli
gener
gp
addit
u
edit
site
nb
contrast
transcript
edit
occur
genom
level
volchkova
et
al
howev
ebov
passag
anim
cell
line
like
cell
genotyp
revert
back
sgp
produc
main
product
transcript
volchkova
et
al
hoenen
et
al
tsuda
et
al
observ
suggest
either
import
function
sgp
import
gp
gene
modul
depend
host
cell
environ
addit
gp
overexpress
cellular
glycosyl
machineri
overwhelm
competit
inhibit
physiolog
process
volchkov
et
al
mohan
et
al
nevertheless
later
stage
viral
infect
gp
get
highli
express
associ
massiv
releas
viral
particl
infect
cell
thu
cytotox
appear
even
situat
control
transcript
edit
howev
viral
particl
produc
point
shown
less
pathogen
suggest
quantit
balanc
gp
express
might
also
requir
regul
infect
mohan
et
al
final
anoth
form
gp
known
shed
gp
gp
dtm
shown
releas
ebolaviru
infect
dolnik
et
al
inde
gp
dtm
releas
surfaceexpress
gp
host
tnfaconvert
enzym
tace
member
disintegrin
metalloproteinas
adam
famili
leav
transmembran
cytoplasm
part
gp
cell
surfac
fig
secret
protein
may
play
role
viral
pathogenesi
block
neutral
antibodi
stimul
ade
might
also
contribut
impair
inflammatori
respons
escuderop
erez
et
al
last
potenti
role
shed
gp
might
modul
endothelium
homeostasi
thu
trigger
increas
vascular
permeabl
dissemin
intravascular
coagul
ultim
caus
multiorgan
failur
death
escuderop
erez
et
al
sinc
filoviru
gp
play
key
role
viru
entri
strategi
target
differ
key
point
process
suppos
block
replic
earli
stage
thu
reduc
chanc
viru
spread
potenti
evolut
toward
drug
resist
therefor
numer
method
target
filoviru
entri
investig
immunebas
therapi
rapidli
develop
review
choi
croyl
lead
effici
monoclon
antibodi
cocktail
oling
et
al
qiu
et
al
qiu
et
al
qiu
et
al
promis
antibodybas
drug
ebolavirus
zmapp
qiu
et
al
ii
altern
peptidebas
antivir
molecul
like
tatebo
analog
design
order
block
cell
membran
fusion
miller
et
al
higgin
et
al
inhibit
base
peptid
limit
interact
block
gp
extens
compound
still
optim
term
treatment
window
dosag
iii
strategi
base
broad
rang
small
molecul
built
disrupt
entri
step
potenti
antivir
compound
heterogen
character
vitro
high
throughput
screen
hit
vivo
studi
review
nyakatura
et
al
rhein
mauri
report
latest
advanc
relat
small
entri
inhibitor
sort
broadspectrum
molecul
filovirusspecif
compound
fdaapprov
therapeut
summar
tabl
regard
antibodybas
therapi
interest
reader
refer
zeitlin
et
al
broadspectrum
molecul
defin
inhibitor
target
key
point
entri
process
effect
multipl
viru
multipl
rna
virus
inde
filovirus
share
entri
step
virus
use
class
envelop
glycoprotein
hiv
influenza
first
target
consid
attach
variou
solubl
mannosespecif
lectin
plant
eg
concanavalin
cyanovirin
n
propos
potenti
antivir
effect
balzarini
et
al
anoth
exampl
griffithsin
lectin
termin
mannos
residu
asparagin
n
link
man
structur
purifi
redalga
might
also
antivir
potenti
sinc
carbohydr
residu
found
hcv
sarscov
relev
discuss
ebolavirus
barton
et
al
similarli
recombin
human
mannos
bind
lectin
shown
mous
model
protect
ebolavirus
michelow
et
al
howev
mous
model
necessari
import
earli
step
drug
evalu
ebolavirus
limit
predict
valu
regard
effect
treatment
stringent
anim
model
evd
even
human
patient
inhibit
catl
catb
involv
ebov
gp
endosom
process
could
also
broadspectrum
antivir
effect
variou
less
specif
inhibitor
describ
unselect
cy
ser
proteas
inhibitor
leupeptin
unselect
cy
proteas
inhibitor
recent
deriv
mix
catl
b
inhibitor
fydmk
specif
catb
inhibitor
nafamostat
mesil
dual
action
also
target
factor
viia
anticoagul
action
catlspecif
inhibitor
oxobarz
zy
tbu
dmk
also
known
triazin
deriv
chandran
et
al
schornberg
et
al
barriento
rollin
shah
et
al
gnirss
et
al
elshabrawi
et
al
nishimura
yamaya
zhou
et
al
van
der
linden
et
al
compound
character
ebolaviru
entri
model
system
pseudotyp
andor
studi
infecti
viru
mechanismbas
suicid
inhibitor
sinc
carri
epoxid
diazomethan
function
group
activ
filovirus
also
sarscov
well
hendra
nipah
virus
elshabrawi
et
al
far
antifiloviru
attach
antiuptak
concern
inhibitor
need
optim
especi
concern
toxic
molecul
target
fusion
constitut
anoth
class
inhibitor
virus
unabl
repair
membran
damag
use
membran
intercal
agent
aryl
methyldien
rhodamin
deriv
wolf
et
al
st
vincent
et
al
rigid
amphipath
fusion
inhibitor
rafi
indol
base
hydrophob
molecul
arbidol
p
echeur
et
al
presum
synthet
oxysterol
liu
et
al
schoggin
randal
teicoplanin
may
impair
virushost
cell
membran
fusion
date
develop
proofofconcept
stage
strategi
show
broad
effici
ebolavirus
influenza
hiv
pox
arena
bunya
herp
paramyxoand
flavivirus
wolf
et
al
broadspectrum
compound
mention
genistein
broad
tyrosin
kinas
inhibitor
tyrphostin
epiderm
growth
factor
receptor
tyrosin
kinas
blocker
trigger
disrupt
endocytosi
endosom
format
use
numer
virus
chandran
et
al
long
known
antimalari
agent
chloroquin
savarino
et
al
show
benefici
effect
endocytosi
exocytosi
increas
endosom
ph
diminut
infg
tnfa
product
sarscov
ebolavirus
vitro
savarino
et
al
keyaert
et
al
keyaert
et
al
madrid
et
al
unfortun
compound
anim
studi
shown
effect
ebolavirus
vivo
dowal
et
al
falzarano
et
al
akpovwa
wherea
compound
still
need
test
model
conclus
regard
effect
made
importantli
differ
vitro
vivo
model
differ
predict
valu
regard
effect
drug
vitro
experi
provid
weakest
evid
although
remain
essenti
start
point
follow
variou
mous
model
wherea
guinea
pig
provid
stringent
model
nonhuman
primat
constitut
stringent
model
balzarini
et
al
barton
et
al
endosom
process
proteas
inhibitor
cy
ser
proteas
inhibitor
leupeptin
chandran
et
al
schornberg
et
al
barriento
et
al
shah
et
al
gnirss
et
al
elshabrawi
et
al
nishimura
et
al
zhou
et
al
van
der
linden
et
al
cy
proteas
inhibitor
catl
catb
inhibitor
fydmk
catb
inhibitor
nafamostat
mesil
catl
inhibitor
oxobarz
zy
tbu
dmk
triazin
deriv
endosom
disrupt
genistein
tyrphostin
chloroquin
savarino
et
al
keyaert
et
al
keyaert
et
al
madrid
et
al
fusion
interc
agent
arbidol
st
vincent
et
al
wolf
et
al
p
echeur
et
al
unclear
oxysterol
teicoplanin
liu
et
al
schoggin
et
al
attach
lectin
competitor
tridecafulleren
et
al
fusion
inhibitor
imipramin
compound
cenedella
e
et
al
kolokoltsov
et
al
lee
et
al
shoemak
et
al
basu
et
al
inhibitor
compound
basu
et
al
approv
drug
target
attach
glycosaminoglycan
competitor
heparin
salvador
et
al
cheng
et
al
ohearn
et
al
uptak
cytoskeleton
inhibitor
vinblastin
vincristin
colchicin
nocodazol
cytochalasin
b
latrunculin
chondramid
kouznetsova
et
al
beck
et
al
endosom
process
g
proteincoupl
receptor
antagonsit
benztropin
mesyl
endosom
ph
increas
omeprazol
esomeprazol
long
et
al
unclear
estrogen
receptor
modul
clomiphen
toremiphen
raloxifen
taxomifen
shoemak
et
al
gehr
et
al
kouznetsova
et
al
sakurai
et
al
zhao
et
al
beck
et
al
ion
channel
inhibitor
amiodaron
dronedaron
verapamil
tetrandin
nimodipin
diltiazem
digoxin
rottlerin
noricumazol
addit
serolog
peptidebas
approach
numer
studi
report
potenti
small
antifiloviru
molecul
compound
sort
three
categori
broadspectrum
molecul
filovirusspecif
compound
repurpos
fdaapprov
therapeut
categori
molecul
arrang
accord
target
entri
process
follow
specif
activ
describ
ebolaviru
marburgviru
diseas
characterist
kept
mind
evalu
antivir
drug
filovirus
interpret
studi
result
compound
target
broad
spectrum
pathogen
virus
howev
sinc
often
target
cellular
machineri
select
toxic
inevit
remain
import
issu
altern
strategi
would
select
molecul
target
filovirus
specif
gp
interact
trigger
fusion
event
filovirus
highli
consid
recent
character
bornholdt
et
al
gong
et
al
zhao
et
al
strategi
challeng
sinc
interfac
gp
larg
dynam
mainli
hydrophob
also
promis
develop
filoviru
specif
antivir
molecul
develop
proteinprotein
interact
inhibitor
toward
gp
report
sever
compound
describ
target
imipramin
cathion
amphiphil
terconazol
adamantan
class
compound
like
benzylpiperazin
adamantan
diamid
late
discov
sulfonamid
deriv
triazol
thioether
deriv
rodriguezlafrass
et
al
cenedella
e
et
al
lee
et
al
shoemak
et
al
basu
et
al
inhibitor
help
identifi
critic
factor
filoviru
entri
interestingli
tertiari
amin
imipramin
inhibit
sphingomyelinas
result
ebolaviru
entri
inhibit
involv
cellular
function
inhibit
disrupt
primari
role
cholesterol
homeostasi
trigger
cholesterol
accumul
endosom
case
niemannpick
diseas
type
c
shoemak
et
al
therefor
develop
might
requir
uncoupl
function
cholesterol
traffic
implic
filoviru
entri
unbundl
tricki
sinc
cholesterol
manag
ebolaviru
bind
facilit
domain
howev
ebolaviru
diseas
constitut
acut
infect
possibl
keep
treatment
time
rel
short
side
effect
might
limit
detriment
effect
practic
altern
strategi
avoid
unwant
hostdirect
effect
might
target
gp
sinc
viral
protein
cellular
homolog
inde
benzodiazepin
deriv
refer
compound
shown
comput
calcul
mutagenesi
mask
hydrophob
conserv
pocket
defin
gp
gp
interfac
inhibit
ebolaviru
replic
basu
et
al
result
also
show
pocket
correspond
trough
rb
suggest
might
anoth
bind
site
steric
regul
region
bind
site
although
mechan
inhibit
yet
clarifi
pocket
rb
pharmacophor
might
key
target
design
filovirusspecif
antivir
molecul
late
anoth
filovirusspecif
strategi
describ
use
tridecafulleren
deriv
compound
et
al
compound
giant
globular
multival
molecul
carri
sugar
motif
abl
compet
lectin
depend
sugar
motif
link
superbal
possibl
target
specif
lectin
target
dcsign
exampl
result
inhibit
ebolaviru
vitro
subnanomolar
concentr
cytotox
notabl
perfect
solubl
water
new
technolog
tridecafulleren
deriv
requir
deeper
investig
depict
mechan
action
vitro
effect
vivo
well
specif
deliveri
target
organ
given
develop
new
therapeut
long
expens
process
one
approach
rapidli
develop
drug
filoviru
infect
reposit
compound
alreadi
approv
nation
intern
health
agenc
kouznetsova
et
al
use
strategi
cation
amphiphil
estrogen
receptor
modul
clomiphen
infertil
treatment
induc
ovul
toremiphen
breast
cancer
chemotherapeut
raloxifen
osteoporosi
prevent
taxomifen
breast
cancer
chemotherapeut
ion
channel
inhibitor
cardiac
arrhythmia
vascular
modul
amiodaron
dronedaron
verapamil
tetrandin
nimodipin
diltiazem
digoxin
rottlerin
shown
inhibit
filoviru
entri
shoemak
et
al
gehr
et
al
kouznetsova
et
al
sakurai
et
al
nelson
et
al
channel
block
compound
noricumazol
myxobacteria
also
describ
potent
inhibitor
beck
et
al
inhibit
mechan
yet
understood
distinct
gp
interactionbas
inhibitor
anoth
group
therapeut
target
cytoskeleton
describ
antiebov
potenti
vinblastin
vincristin
colchicin
nocodazol
cytochalasin
b
latrunculin
other
kouznetsova
et
al
beck
et
al
howev
molecul
suppos
quit
toxic
sinc
mostli
use
anticanc
chemotherapi
addit
larg
class
approv
therapeut
g
proteincoupl
receptor
gpcr
antagonist
screen
benzotropin
mesyl
initi
use
parkinson
diseas
exhibit
vitro
antifiloviru
activ
target
postattach
step
molecul
deserv
thorough
mechanist
investig
sinc
literatur
mention
involv
gpcr
filoviru
entri
drug
omeprazol
esomeprazol
acid
reflux
diseas
offtarget
inhibitori
activ
trigger
increas
endosom
ph
inhibit
late
entri
event
filoviru
infect
long
et
al
also
sever
studi
describ
heparin
potent
inhibitor
earli
attach
corecept
via
glycosaminoglycan
salvador
et
al
cheng
et
al
ohearn
et
al
howev
studi
need
unravel
antivir
mechan
fdaapprov
compound
although
compound
alreadi
pass
safeti
test
import
underlin
dose
treatment
window
like
critic
issu
use
antibodi
zmapp
demonstr
inhibitor
target
filoviru
entri
might
provid
potent
antivir
strategi
howev
develop
small
molecul
inhibit
crucial
viral
step
still
hamper
insuffici
molecular
character
attachmentuptak
mechan
multipl
molecular
event
occur
endosom
compart
date
identif
main
charact
clear
finetun
step
clarifi
inhibitor
present
herein
appear
function
sever
entri
step
suscept
one
yet
identifi
target
prefus
gp
gp
interfac
might
repres
best
strategi
develop
filovirusspecif
treatment
integr
vision
mind
antivir
therapi
might
advantag
complement
vaccin
serolog
therapi
filoviru
outbreak
simpl
logist
especi
west
central
africa
